Loading news...
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET.
Precipio (NASDAQ: PRPO - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of recent ratings
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M
Precipio, Inc. (NASDAQ: PRPO - Get Free Report) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 4,048 shares, a growth of 22.5% from the January 15th total of 3,304 shares. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4
Precipio, Inc. (NASDAQ: PRPO - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $20.29 and traded as low as $19.52. Precipio shares last traded at $19.80, with a volume of 32,703 shares trading hands. Analyst Upgrades and Downgrades A number of
Precipio (NASDAQ: PRPO - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Institutional and Insider Ownership 10.5% of Precipio shares
Precipio, Inc. (NASDAQ: PRPO - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 4,991 shares, an increase of 21.0% from the December 15th total of 4,124 shares. Currently, 0.3% of the company's shares are short sold. Based on an average
AMH Equity Ltd lifted its stake in shares of Precipio, Inc. (NASDAQ: PRPO) by 370.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 131,100 shares of the biotechnology company's stock after acquiring an additional 103,210 shares during the quarter. Precipio comprises
Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding
Precipio (NASDAQ: PRPO - Get Free Report) and Tivic Health Systems (NASDAQ: TIVC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends. Profitability This table compares Precipio and Tivic
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Precipio (NASDAQ: PRPO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends. Volatility and Risk Health Catalyst has a beta
Precipio (NASDAQ: PRPO - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings. Risk and Volatility Precipio has a beta of
Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances.
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
Precipio, Inc. ( PRPO ) Q3 2025 Earnings Call November 17, 2025 5:00 PM EST Company Participants Ilan Danieli - Founder, President, CEO & Director Presentation Operator Welcome to the Precipio Third Quarter 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that the conference is being recorded.
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter
NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET.
Precipio, Inc. (NASDAQ:PRPO ) Q2 2025 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Operator Welcome to the Precipio Q2 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that this conference is being recorded.
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today.